However, more recent studies show that rotational behavior can only be used as an indicator of L-DOPA-induced locomotor activity (Tronci and Francardo 2018), especially because amantadine, the only anti-diskinetic drug used in the clinic (Perez-Lloret and Rascol 2018), and genetic interventions aimed to reduce the severity of dyskinesia (i.e. RasGRF1 inactivation) (Fasano et al. 2010; Lundblad et al. 2005) had no effect on the number of contralateral rotations. The gene discussed is RASGRF1; the disease is Dyskinesia.